The MD Labs Medical-Necessity Lessons: What the Public Record Teaches Every Lab

Few phrases carry more weight in a toxicology lab than medical necessity. It is the line between a test that gets paid and a test that gets clawed back, and in the harder cases, the line between a defensible business and a False Claims Act headline. The public record around MD Labs — a toxicology laboratory that has been on both sides of that line — is one of the more instructive case studies an operator can study. Not because of the drama, but because of what it teaches about documentation.

We are not here to celebrate or condemn another lab. We are here to pull the operational lesson out of the public record, because the same lesson protects your lab whether you ever see a courtroom or not.

Two chapters, one dividing line

The MD Labs story, as reflected in publicly reported government announcements and court decisions, has two very different chapters.

In the first, MD Labs and its co-founders agreed in 2021 to resolve federal False Claims Act allegations — for a figure reported at up to $16 million — tied to presumptive urine drug testing. The government's theory, as described publicly, was straightforward: when a provider has already ordered definitive (confirmatory) testing and would not act on a presumptive result, billing for that presumptive test is hard to justify as medically necessary. A settlement is not an admission of liability. But the shape of the allegation is the lesson: testing that the treating clinician would not actually use to make a decision is testing that is difficult to defend.

In the second chapter, MD Labs and its owners won. In a separate whistleblower suit alleging improper billing related to PCR testing, a federal court granted summary judgment in the lab's favor and dismissed the claims, and that outcome was affirmed on appeal in a decision reported in late 2025. The court, in essence, found the fraud theory unsupported by the facts.

Same company. Opposite outcomes. The variable that changed was whether the testing — and the record behind it — could be defended as clinically necessary.

What actually separates the two outcomes

It is tempting to read a courtroom win as vindication of everything a lab does, and a settlement as proof of wrongdoing. Both readings are lazy. The more useful reading is narrower and more valuable: medical necessity is adjudicated test by test, record by record. A lab can be indefensible on one line item and completely defensible on another. The paperwork is what decides which is which.

When testing is ordered with a clear clinical purpose, documented against a real diagnosis, and used by the treating provider to change management, it holds up — even under the scrutiny of a whistleblower suit. When testing is reflexive, bundled, or ordered in a pattern that no clinician is actually acting on, it does not, no matter how accurate the assay itself was. This is the entire thesis of our medical necessity guide, and it is especially unforgiving in toxicology.

Toxicology is the deep end

Urine drug testing draws more audit attention than almost any other category of lab work, and the presumptive-versus-definitive question sits at the center of it. The government's recurring concern is a familiar one: presumptive and definitive testing billed together as a standing pattern, rather than definitive testing ordered because a specific presumptive result — or a specific clinical question — required confirmation.

The defensible posture is not complicated to state, even if it is demanding to execute:

• Order with intent. Every test should map to a clinical question the ordering provider is actually asking. No standing panels running on autopilot.
• Document the necessity at the point of order, not reconstructed months later when the audit letter arrives.
• Separate presumptive and definitive logic. If a definitive test is billed, the record should show why confirmation was warranted for that patient.
• Justify frequency. Repeat testing needs a reason that lives in the chart, tied to the patient's treatment stage or risk.
• Keep it audit-ready by default, because the difference between the MD Labs settlement and the MD Labs win is, at bottom, the difference between records that survive scrutiny and records that do not.

We go deeper on the toxicology-specific mechanics in documenting medical necessity for drug testing.

The operator's takeaway

The reason this matters to every lab — not just labs that end up in litigation — is that the enforcement environment is not softening. Whistleblower suits are a permanent feature of the landscape, and the government has shown it will pursue toxicology billing aggressively. You do not get to choose whether your medical-necessity documentation is examined. You only get to choose whether it is ready when it is.

That readiness is not a binder someone assembles the week before an inspection. It is a property of how your lab operates every day: whether necessity is captured at order entry, whether coverage logic is enforced before a claim goes out, whether the clinical rationale is attached to the test rather than to someone's memory. Labs that bolt compliance on after the fact live one audit away from a bad quarter. Labs that build necessity into the workflow can defend their work as a matter of routine — which is exactly the argument for running your lab on one operational system rather than a stack of disconnected tools.

• Medical necessity is decided test by test — a lab can be defensible on one line and not another.
• Toxicology, especially presumptive-plus-definitive billing, draws the most scrutiny.
• The dividing line between an enforcement action and a courtroom win is documentation that holds up.
• Audit-readiness is an operating discipline, not a last-minute project.

Study the public record not for the verdict but for the mechanism. The labs that survive this environment are the ones that treat medical-necessity documentation as core operational infrastructure. See how coverage-aware ordering looks in practice on the LabX test menu, and read why over-compliance hits small labs hardest — because the labs with the least margin for error are the ones that most need to get this right the first time.

This article discusses matters of public record for educational purposes and reflects general reporting on government announcements and court decisions. It is not legal advice, and a settlement is not an admission of liability. Labs should consult qualified compliance and legal counsel regarding their own billing practices.